Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lamivudine in p53 Mutant Metastatic Colorectal Cancer
NCT03144804Phase 2Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Oct 2017
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lamivudine in colorectal cancer (CRC), sponsored by Massachusetts General Hospital. Started Oct 2017; status: completed.
02
Drugs
lamivudine
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03144804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03144804.